Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Investigating the Effect of Pericapsular Nerve Group (PENG) Block on Postoperative Pain After Peri-acetabular Osteotomy

The aim of this study is to determine the effect of PENG blockade on postoperative pain after either ropivacaine 5 mg/mL or saline (placebo) in patients undergoing PAO. The hypothesis of this study is that PENG block with ropivacaine reduces postoperative pain compared to placebo (saline).

Participants needed: 90
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Matias VestedUpdated: Aug 26, 2025Locations: 1
Eligibility criteria

Patients ≥ 18 years old [+4]

Known allergy to ropivacaine [+2]

Status: Recruiting

Neuromuscular Monitoring in Children (6 Months - 2 Years) With Electromyography and Acceleromyography

The aim of this study is to compare AMG and EMG (Philips IntelliVue NMT module and Senzime TetraGraph) in the objective monitoring of neuromuscular blocking in children between the age of 6 months and 2 years.The monitoring will be done bilaterally either on n.ulnaris or n. tibialis. The hypothesis of the study is that AMG will indicate faster recovery time (time to return to TOF 90%) from neuromuscular block than EMG.

Participants needed: 120
Trial details
Age: 6-2Biological sex: AllType: InterventionalSponsor: Matias VestedUpdated: Aug 26, 2025Locations: 1
Eligibility criteria

Patients 6 months - 2 years of age [+2]

Known allergy to rocuronium [+3]

Status: Recruiting

Ephedrine for Reducing Onset Time of Rocurinium in Elderly Patients

The aim of this study is to determine the onset time of rocuronium after administration of ephedrine 0.15 mg/kg in patients with age ≥ 80 years. The hypothesis of this study is that ephedrine 0.15 mg/kg provides a shorter onset time compared to placebo (saline).

Participants needed: 80
Trial details
Phase: Phase 4Age: 80+Biological sex: AllType: InterventionalSponsor: Matias VestedUpdated: Jan 17, 2025Locations: 2
Eligibility criteria

Age ≥ 80 [+4]

Known allergy to rocuronium or ephedrine [+4]